These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 9814943)
21. The International AIDS Vaccine Initiative. Berkley S J Int Assoc Physicians AIDS Care; 1997 Nov; 3(11):30-4. PubMed ID: 11364811 [TBL] [Abstract][Full Text] [Related]
22. Vaccine approaches currently in development. Gold D Body Posit; 1998 Jul; 11(7):34-5. PubMed ID: 11365616 [TBL] [Abstract][Full Text] [Related]
23. Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative. Tucker TJ; Mazithulela G BMJ; 2004 Aug; 329(7463):454-6. PubMed ID: 15321907 [TBL] [Abstract][Full Text] [Related]
25. Update on HIV vaccines. Meldorf M; Corey L STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929 [TBL] [Abstract][Full Text] [Related]
26. Eureka! Success of combo HIV vaccine raises hopes, should revitalize research. An HIV vaccine shows surprising efficacy in human trials. AIDS Alert; 2009 Nov; 24(11):121-3. PubMed ID: 19960605 [No Abstract] [Full Text] [Related]
27. US and Thai Governments defend HIV/AIDS vaccine trial in Thailand. Agnew B Bull World Health Organ; 2004 Mar; 82(3):231. PubMed ID: 15112014 [No Abstract] [Full Text] [Related]
29. The challenges of an HIV vaccine enterprise. Wolf H Science; 2004 Feb; 303(5662):1294-7; author reply 1294-7. PubMed ID: 14991961 [No Abstract] [Full Text] [Related]
30. HIV vaccine development. Johnston MI Dev Biol (Basel); 2002; 110():57-63. PubMed ID: 12477307 [TBL] [Abstract][Full Text] [Related]
31. G-8 endorses new global HIV vaccine enterprise. Bull World Health Organ; 2004 Jul; 82(7):557. PubMed ID: 15500292 [No Abstract] [Full Text] [Related]
32. Development of research capability in Ethiopia: the Ethio-Netherlands AIDS research project (ENARP): 1994-2002, achievements, scientific findings and project goals. Sanders EJ; Messele T; Wolday D; Dorigo-Zetsma W; WoldeMichael T; Geyid A; Coutinho R Ethiop Med J; 2003 Jun; 41 Suppl 1():11-23. PubMed ID: 15227876 [TBL] [Abstract][Full Text] [Related]
33. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Ferrantelli F; Cafaro A; Ensoli B Curr Opin Biotechnol; 2004 Dec; 15(6):543-56. PubMed ID: 15560981 [TBL] [Abstract][Full Text] [Related]
35. HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries. Maponga CC; Ma Q; Slish JC; Morse GD Top HIV Med; 2007; 15(3):104-10. PubMed ID: 17598930 [TBL] [Abstract][Full Text] [Related]
36. Environmental factors in HIV/AIDS epidemic development: new perspectives for gender equity and global protection against HIV transmission. Alfsen A Ann N Y Acad Sci; 2004 Jun; 1023():164-74. PubMed ID: 15253905 [TBL] [Abstract][Full Text] [Related]
37. Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience. Ferrantelli F; Buttò S; Cafaro A; Wahren B; Ensoli B Springer Semin Immunopathol; 2006 Nov; 28(3):289-301. PubMed ID: 16983452 [TBL] [Abstract][Full Text] [Related]
38. New institute to focus on AIDS vaccine. AIDS Read; 2008 Nov; 18(11):551. PubMed ID: 19058408 [No Abstract] [Full Text] [Related]
39. Partnership for HIV vaccine research in Africa. Sanders E Ethiop Med J; 2003 Jun; 41 Suppl 1():5-7. PubMed ID: 15227875 [No Abstract] [Full Text] [Related]
40. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines. Blower S; Schwartz EJ; Mills J AIDS Rev; 2003; 5(2):113-25. PubMed ID: 12876900 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]